APO Research
Talk to an analyst

APO RESEARCH · REPORT

Oncology Immuno Drug

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Oncology Immuno Drug Industry Growth and Trends Forecast to 2032

2 January 202692 pages

Choose your research edition.

Industry ResearchOncology Immuno Drug Industry Research Report 2026117 pages · $2,950 USDIndustry Growth & TrendsGlobal Oncology Immuno Drug Industry Growth and Trends Forecast to 203292 pages · $3,450 USDMarket StructureGlobal Oncology Immuno Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032187 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Oncology Immuno Drug Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Oncology Immuno Drug Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Oncology Immuno Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Oncology Immuno Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Oncology Immuno Drug is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Oncology Immuno Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Oncology Immuno Drug include Bristol-Myers Squibb, Dendreon Pharmaceuticals, Gilead Sciences Inc., Merck & Co, Sanofi S.A., AstraZeneca, Roche AG, Merck KGaA and Novartis, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Oncology Immuno Drug market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Oncology Immuno Drug market size, estimates, and forecasts are presented in terms of sales volume (K Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Oncology Immuno Drug market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Oncology Immuno Drug.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Oncology Immuno Drug market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Oncology Immuno Drug Market by Company

Bristol-Myers Squibb

Dendreon Pharmaceuticals

Gilead Sciences Inc.

Merck & Co

Sanofi S.A.

AstraZeneca

Roche AG

Merck KGaA

Novartis

Oncology Immuno Drug Segment by Type

CAR-T Cell Therapy

Cancer Vaccines

Cytokine-Based Immunotherapy

Immune Checkpoint Inhibitors

Other

Oncology Immuno Drug Segment by Application

Hospitals

Drugstores

Others

Oncology Immuno Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Oncology Immuno Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Oncology Immuno Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Oncology Immuno Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Oncology Immuno Drug manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Oncology Immuno Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of CAR-T Cell Therapy Table 2. Major Company of Cancer Vaccines Table 3. Major Company of Cytokine-Based Immunotherapy Table 4. Major Company of Immune Checkpoint Inhibitors Table 5. Major Company of Other Table 6. Global Oncology Immuno Drug Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 7. Global Oncology Immuno Drug Sales by Type (2021-2026) & (K Units) Table 8. Global Oncology Immuno Drug Sales Market Share in Volume by Type (2021-2026) Table 9. Global Oncology Immuno Drug Sales by Type (2021-2026) & (US$ Million) Table 10. Global Oncology Immuno Drug Sales Market Share in Value by Type (2021-2026) Table 11. Global Oncology Immuno Drug Price by Type (2021-2026) & (US$/Unit) Table 12. Global Oncology Immuno Drug Sales by Type (2027-2032) & (K Units) Table 13. Global Oncology Immuno Drug Sales Market Share in Volume by Type (2027-2032) Table 14. Global Oncology Immuno Drug Sales by Type (2027-2032) & (US$ Million) Table 15. Global Oncology Immuno Drug Sales Market Share in Value by Type (2027-2032) Table 16. Global Oncology Immuno Drug Price by Type (2027-2032) & (US$/Unit) Table 17. North America Oncology Immuno Drug Sales by Type (2021-2026) & (K Units) Table 18. North America Oncology Immuno Drug Sales by Type (2021-2026) & (US$ Million) Table 19. Europe Oncology Immuno Drug Sales by Type (2021-2026) & (K Units) Table 20. Europe Oncology Immuno Drug Sales by Type (2021-2026) & (US$ Million) Table 21. Asia-Pacific Oncology Immuno Drug Sales by Type (2021-2026) & (K Units) Table 22. Asia-Pacific Oncology Immuno Drug Sales by Type (2021-2026) & (US$ Million) Table 23. Latin America Oncology Immuno Drug Sales by Type (2021-2026) & (K Units) Table 24. Latin America Oncology Immuno Drug Sales by Type (2021-2026) & (US$ Million) Table 25. Middle East and Africa Oncology Immuno Drug Sales by Type (2021-2026) & (K Units) Table 26. Middle East and Africa Oncology Immuno Drug Sales by Type (2021-2026) & (US$ Million) Table 27. Oncology Immuno Drug Industry Trends Table 28. Oncology Immuno Drug Industry Drivers Table 29. Oncology Immuno Drug Industry Opportunities and Challenges Table 30. Oncology Immuno Drug Industry Restraints Table 31. Global Oncology Immuno Drug Sales Revenue by Company (US$ Million) & (2021-2026) Table 32. Global Oncology Immuno Drug Revenue Market Share by Company (2021-2026) Table 33. Global Oncology Immuno Drug Sales by Company (2021-2026) & (K Units) Table 34. Global Oncology Immuno Drug Sales Share by Company (2021-2026) Table 35. Global Oncology Immuno Drug Market Price by Company (2021-2026) & (US$/Unit) Table 36. Global Oncology Immuno Drug Industry Company Ranking, 2024 VS 2025 VS 2026 Table 37. Global Oncology Immuno Drug Major Company Production Sites and Headquarters Table 38. Global Oncology Immuno Drug Company, Product Type & Application Table 39. Global Oncology Immuno Drug Company Establishment Date Table 40. Global Company Market Concentration Ratio (CR5 and HHI) Table 41. Global Oncology Immuno Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 42. Global Oncology Immuno Drug Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 43. Global Oncology Immuno Drug Sales by Region (2021-2026) & (K Units) Table 44. Global Oncology Immuno Drug Sales Market Share in Volume by Region (2021-2026) Table 45. Global Oncology Immuno Drug Sales by Region (2021-2026) & (US$ Million) Table 46. Global Oncology Immuno Drug Sales Market Share in Value by Region (2021-2026) Table 47. Global Oncology Immuno Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 48. Global Oncology Immuno Drug Sales by Region (2027-2032) & (K Units) Table 49. Global Oncology Immuno Drug Sales Market Share in Volume by Region (2027-2032) Table 50. Global Oncology Immuno Drug Sales by Region (2027-2032) & (US$ Million) Table 51. Global Oncology Immuno Drug Sales Market Share in Value by Region (2027-2032) Table 52. Global Oncology Immuno Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 53. Global Oncology Immuno Drug Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 54. Global Oncology Immuno Drug Sales by Application (2021-2026) & (K Units) Table 55. Global Oncology Immuno Drug Sales Market Share in Volume by Application (2021-2026) Table 56. Global Oncology Immuno Drug Sales by Application (2021-2026) & (US$ Million) Table 57. Global Oncology Immuno Drug Sales Market Share in Value by Application (2021-2026) Table 58. Global Oncology Immuno Drug Price by Application (2021-2026) & (US$/Unit) Table 59. Global Oncology Immuno Drug Sales by Application (2027-2032) & (K Units) Table 60. Global Oncology Immuno Drug Sales Market Share in Volume by Application (2027-2032) Table 61. Global Oncology Immuno Drug Sales by Application (2027-2032) & (US$ Million) Table 62. Global Oncology Immuno Drug Sales Market Share in Value by Application (2027-2032) Table 63. Global Oncology Immuno Drug Price by Application (2027-2032) & (US$/Unit) Table 64. North America Oncology Immuno Drug Sales by Application (2021-2026) & (K Units) Table 65. North America Oncology Immuno Drug Sales by Application (2021-2026) & (US$ Million) Table 66. Europe Oncology Immuno Drug Sales by Application (2021-2026) & (K Units) Table 67. Europe Oncology Immuno Drug Sales by Application (2021-2026) & (US$ Million) Table 68. Asia-Pacific Oncology Immuno Drug Sales by Application (2021-2026) & (K Units) Table 69. Asia-Pacific Oncology Immuno Drug Sales by Application (2021-2026) & (US$ Million) Table 70. Latin America Oncology Immuno Drug Sales by Application (2021-2026) & (K Units) Table 71. Latin America Oncology Immuno Drug Sales by Application (2021-2026) & (US$ Million) Table 72. Middle East and Africa Oncology Immuno Drug Sales by Application (2021-2026) & (K Units) Table 73. Middle East and Africa Oncology Immuno Drug Sales by Application (2021-2026) & (US$ Million) Table 74. Bristol-Myers Squibb Company Information Table 75. Bristol-Myers Squibb Business Overview Table 76. Bristol-Myers Squibb Oncology Immuno Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. Bristol-Myers Squibb Oncology Immuno Drug Product Portfolio Table 78. Bristol-Myers Squibb Recent Development Table 79. Dendreon Pharmaceuticals Company Information Table 80. Dendreon Pharmaceuticals Business Overview Table 81. Dendreon Pharmaceuticals Oncology Immuno Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. Dendreon Pharmaceuticals Oncology Immuno Drug Product Portfolio Table 83. Dendreon Pharmaceuticals Recent Development Table 84. Gilead Sciences Inc. Company Information Table 85. Gilead Sciences Inc. Business Overview Table 86. Gilead Sciences Inc. Oncology Immuno Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. Gilead Sciences Inc. Oncology Immuno Drug Product Portfolio Table 88. Gilead Sciences Inc. Recent Development Table 89. Merck & Co Company Information Table 90. Merck & Co Business Overview Table 91. Merck & Co Oncology Immuno Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Merck & Co Oncology Immuno Drug Product Portfolio Table 93. Merck & Co Recent Development Table 94. Sanofi S.A. Company Information Table 95. Sanofi S.A. Business Overview Table 96. Sanofi S.A. Oncology Immuno Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. Sanofi S.A. Oncology Immuno Drug Product Portfolio Table 98. Sanofi S.A. Recent Development Table 99. AstraZeneca Company Information Table 100. AstraZeneca Business Overview Table 101. AstraZeneca Oncology Immuno Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. AstraZeneca Oncology Immuno Drug Product Portfolio Table 103. AstraZeneca Recent Development Table 104. Roche AG Company Information Table 105. Roche AG Business Overview Table 106. Roche AG Oncology Immuno Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. Roche AG Oncology Immuno Drug Product Portfolio Table 108. Roche AG Recent Development Table 109. Merck KGaA Company Information Table 110. Merck KGaA Business Overview Table 111. Merck KGaA Oncology Immuno Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 112. Merck KGaA Oncology Immuno Drug Product Portfolio Table 113. Merck KGaA Recent Development Table 114. Novartis Company Information Table 115. Novartis Business Overview Table 116. Novartis Oncology Immuno Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 117. Novartis Oncology Immuno Drug Product Portfolio Table 118. Novartis Recent Development Table 119. North America Oncology Immuno Drug Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 120. North America Oncology Immuno Drug Sales by Country (2021-2026) & (K Units) Table 121. North America Oncology Immuno Drug Sales Market Share by Country (2021-2026) Table 122. North America Oncology Immuno Drug Sales Forecast by Country (2027-2032) & (K Units) Table 123. North America Oncology Immuno Drug Sales Market Share Forecast by Country (2027-2032) Table 124. North America Oncology Immuno Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 125. North America Oncology Immuno Drug Market Size by Country (2021-2026) & (US$ Million) Table 126. North America Oncology Immuno Drug Market Share by Country (2021-2026) Table 127. North America Oncology Immuno Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 128. North America Oncology Immuno Drug Market Share Forecast by Country (2027-2032) Table 129. Europe Oncology Immuno Drug Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 130. Europe Oncology Immuno Drug Sales by Country (2021-2026) & (K Units) Table 131. Europe Oncology Immuno Drug Sales Market Share by Country (2021-2026) Table 132. Europe Oncology Immuno Drug Sales Forecast by Country (2027-2032) & (K Units) Table 133. Europe Oncology Immuno Drug Sales Market Share Forecast by Country (2027-2032) Table 134. Europe Oncology Immuno Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 135. Europe Oncology Immuno Drug Market Size by Country (2021-2026) & (US$ Million) Table 136. Europe Oncology Immuno Drug Market Share by Country (2021-2026) Table 137. Europe Oncology Immuno Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 138. Europe Oncology Immuno Drug Market Share Forecast by Country (2027-2032) Table 139. Asia-Pacific Oncology Immuno Drug Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 140. Asia-Pacific Oncology Immuno Drug Sales by Country (2021-2026) & (K Units) Table 141. Asia-Pacific Oncology Immuno Drug Sales Market Share by Country (2021-2026) Table 142. Asia-Pacific Oncology Immuno Drug Sales Forecast by Country (2027-2032) & (K Units) Table 143. Asia-Pacific Oncology Immuno Drug Sales Market Share Forecast by Country (2027-2032) Table 144. Asia-Pacific Oncology Immuno Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 145. Asia-Pacific Oncology Immuno Drug Market Size by Country (2021-2026) & (US$ Million) Table 146. Asia-Pacific Oncology Immuno Drug Market Share by Country (2021-2026) Table 147. Asia-Pacific Oncology Immuno Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 148. Asia-Pacific Oncology Immuno Drug Market Share Forecast by Country (2027-2032) Table 149. Latin America Oncology Immuno Drug Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 150. Latin America Oncology Immuno Drug Sales by Country (2021-2026) & (K Units) Table 151. Latin America Oncology Immuno Drug Sales Market Share by Country (2021-2026) Table 152. Latin America Oncology Immuno Drug Sales Forecast by Country (2027-2032) & (K Units) Table 153. Latin America Oncology Immuno Drug Sales Market Share Forecast by Country (2027-2032) Table 154. Latin America Oncology Immuno Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 155. Latin America Oncology Immuno Drug Market Size by Country (2021-2026) & (US$ Million) Table 156. Latin America Oncology Immuno Drug Market Share by Country (2021-2026) Table 157. Latin America Oncology Immuno Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 158. Latin America Oncology Immuno Drug Market Share Forecast by Country (2027-2032) Table 159. Middle East and Africa Oncology Immuno Drug Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 160. Middle East and Africa Oncology Immuno Drug Sales by Country (2021-2026) & (K Units) Table 161. Middle East and Africa Oncology Immuno Drug Sales Market Share by Country (2021-2026) Table 162. Middle East and Africa Oncology Immuno Drug Sales Forecast by Country (2027-2032) & (K Units) Table 163. Middle East and Africa Oncology Immuno Drug Sales Market Share Forecast by Country (2027-2032) Table 164. Middle East and Africa Oncology Immuno Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 165. Middle East and Africa Oncology Immuno Drug Market Size by Country (2021-2026) & (US$ Million) Table 166. Middle East and Africa Oncology Immuno Drug Market Share by Country (2021-2026) Table 167. Middle East and Africa Oncology Immuno Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 168. Middle East and Africa Oncology Immuno Drug Market Share Forecast by Country (2027-2032) Table 169. Key Raw Materials Table 170. Raw Materials Key Suppliers Table 171. Oncology Immuno Drug Distributors List Table 172. Oncology Immuno Drug Customers List Table 173. Research Programs/Design for This Report Table 174. Authors List of This Report Table 175. Secondary Sources Table 176. Primary Sources List of Figures Figure 1. Oncology Immuno Drug Image Figure 2. Global Oncology Immuno Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Oncology Immuno Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Oncology Immuno Drug Sales (2021-2032) & (K Units) Figure 5. CAR-T Cell Therapy Image Figure 6. Global CAR-T Cell Therapy Sales YoY Growth (2021-2032) & (K Units) Figure 7. Cancer Vaccines Image Figure 8. Global Cancer Vaccines Sales YoY Growth (2021-2032) & (K Units) Figure 9. Cytokine-Based Immunotherapy Image Figure 10. Global Cytokine-Based Immunotherapy Sales YoY Growth (2021-2032) & (K Units) Figure 11. Immune Checkpoint Inhibitors Image Figure 12. Global Immune Checkpoint Inhibitors Sales YoY Growth (2021-2032) & (K Units) Figure 13. Other Image Figure 14. Global Other Sales YoY Growth (2021-2032) & (K Units) Figure 15. Global Oncology Immuno Drug Market Size Overview by Type (2021-2032) & (US$ Million) Figure 16. Global Oncology Immuno Drug Market Share by Type 2025 VS 2032 Figure 17. North America Oncology Immuno Drug Sales Market Share in Volume by Type in 2025 Figure 18. North America Oncology Immuno Drug Sales Market Share in Value by Type in 2025 Figure 19. Europe Oncology Immuno Drug Sales Market Share in Volume by Type in 2025 Figure 20. Europe Oncology Immuno Drug Sales Market Share in Value by Type in 2025 Figure 21. Asia-Pacific Oncology Immuno Drug Sales Market Share in Volume by Type in 2025 Figure 22. Asia-Pacific Oncology Immuno Drug Sales Market Share in Value by Type in 2025 Figure 23. Latin America Oncology Immuno Drug Sales Market Share in Volume by Type in 2025 Figure 24. Latin America Oncology Immuno Drug Sales Market Share in Value by Type in 2025 Figure 25. Middle East and Africa Oncology Immuno Drug Sales Market Share in Volume by Type in 2025 Figure 26. Middle East and Africa Oncology Immuno Drug Sales Market Share in Value by Type in 2025 Figure 27. Global Top 5 and 10 Oncology Immuno Drug Players Market Share by Revenue in 2025 Figure 28. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 29. Hospitals Image Figure 30. Global Hospitals Sales YoY Growth (2021-2032) & (K Units) Figure 31. Drugstores Image Figure 32. Global Drugstores Sales YoY Growth (2021-2032) & (K Units) Figure 33. Others Image Figure 34. Global Others Sales YoY Growth (2021-2032) & (K Units) Figure 35. Global Oncology Immuno Drug Market Size Overview by Application (2021-2032) & (US$ Million) Figure 36. Global Oncology Immuno Drug Market Share by Application 2025 VS 2032 Figure 37. North America Oncology Immuno Drug Sales Market Share in Volume by Application in 2025 Figure 38. North America Oncology Immuno Drug Sales Market Share in Value by Application in 2025 Figure 39. Europe Oncology Immuno Drug Sales Market Share in Volume by Application in 2025 Figure 40. Europe Oncology Immuno Drug Sales Market Share in Value by Application in 2025 Figure 41. Asia-Pacific Oncology Immuno Drug Sales Market Share in Volume by Application in 2025 Figure 42. Asia-Pacific Oncology Immuno Drug Sales Market Share in Value by Application in 2025 Figure 43. Latin America Oncology Immuno Drug Sales Market Share in Volume by Application in 2025 Figure 44. Latin America Oncology Immuno Drug Sales Market Share in Value by Application in 2025 Figure 45. Middle East and Africa Oncology Immuno Drug Sales Market Share in Volume by Application in 2025 Figure 46. Middle East and Africa Oncology Immuno Drug Sales Market Share in Value by Application in 2025 Figure 47. North America Oncology Immuno Drug Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 48. North America Oncology Immuno Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 49. North America Oncology Immuno Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 50. North America Oncology Immuno Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 51. Europe Oncology Immuno Drug Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 52. Europe Oncology Immuno Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 53. Europe Oncology Immuno Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 54. Europe Oncology Immuno Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 55. Asia-Pacific Oncology Immuno Drug Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 56. Asia-Pacific Oncology Immuno Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 57. Asia-Pacific Oncology Immuno Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Asia-Pacific Oncology Immuno Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 59. Latin America Oncology Immuno Drug Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 60. Latin America Oncology Immuno Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 61. Latin America Oncology Immuno Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 62. Latin America Oncology Immuno Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 63. Middle East and Africa Oncology Immuno Drug Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 64. Middle East and Africa Oncology Immuno Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 65. Middle East and Africa Oncology Immuno Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 66. Middle East and Africa Oncology Immuno Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 67. Oncology Immuno Drug Value Chain Figure 68. Key Raw Materials Price Figure 69. Manufacturing Cost Structure Figure 70. Oncology Immuno Drug Production Mode & Process Figure 71. Direct Comparison with Distribution Share Figure 72. Distributors Profiles Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • CAR-T Cell Therapy
  • Cancer Vaccines
  • Cytokine-Based Immunotherapy
  • Immune Checkpoint Inhibitors
  • Other
Applications
  • Hospitals
  • Drugstores
  • Others
Companies covered
  • Bristol-Myers Squibb
  • Dendreon Pharmaceuticals
  • Gilead Sciences Inc.
  • Merck & Co
  • Sanofi S.A.
  • AstraZeneca
  • Roche AG
  • Merck KGaA
  • Novartis

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Oncology Immuno Drug Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Oncology Immuno Drug Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Oncology Immuno Drug Market by Type
  6. 1.3.1 CAR-T Cell Therapy
  7. 1.3.2 Cancer Vaccines
  8. 1.3.3 Cytokine-Based Immunotherapy
  9. 1.3.4 Immune Checkpoint Inhibitors
  10. 1.3.5 Other
  11. 1.4 Global Oncology Immuno Drug Market Size by Type
  12. 1.4.1 Global Oncology Immuno Drug Market Size Overview by Type (2021-2032)
  13. 1.4.2 Global Oncology Immuno Drug Historic Market Size Review by Type (2021-2026)
  14. 1.4.3 Global Oncology Immuno Drug Forecasted Market Size by Type (2027-2032)
  15. 1.5 Key Regions Market Size by Type
  16. 1.5.1 North America Oncology Immuno Drug Sales Breakdown by Type (2021-2026)
  17. 1.5.2 Europe Oncology Immuno Drug Sales Breakdown by Type (2021-2026)
  18. 1.5.3 Asia-Pacific Oncology Immuno Drug Sales Breakdown by Type (2021-2026)
  19. 1.5.4 South America Oncology Immuno Drug Sales Breakdown by Type (2021-2026)
  20. 1.5.5 Middle East and Africa Oncology Immuno Drug Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Oncology Immuno Drug Industry Trends
  2. 2.2 Oncology Immuno Drug Industry Drivers
  3. 2.3 Oncology Immuno Drug Industry Opportunities and Challenges
  4. 2.4 Oncology Immuno Drug Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Oncology Immuno Drug Revenue (2021-2026)
  2. 3.2 Global Top Players by Oncology Immuno Drug Sales (2021-2026)
  3. 3.3 Global Top Players by Oncology Immuno Drug Price (2021-2026)
  4. 3.4 Global Oncology Immuno Drug Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Oncology Immuno Drug Major Company Production Sites & Headquarters
  6. 3.6 Global Oncology Immuno Drug Company, Product Type & Application
  7. 3.7 Global Oncology Immuno Drug Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Oncology Immuno Drug Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Oncology Immuno Drug Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Oncology Immuno Drug Tier 1, Tier 2, and Tier 3
4 Oncology Immuno Drug Regional Status and Outlook
  1. 4.1 Global Oncology Immuno Drug Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Oncology Immuno Drug Historic Market Size by Region
  3. 4.2.1 Global Oncology Immuno Drug Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Oncology Immuno Drug Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Oncology Immuno Drug Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Oncology Immuno Drug Forecasted Market Size by Region
  7. 4.3.1 Global Oncology Immuno Drug Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Oncology Immuno Drug Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Oncology Immuno Drug Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Oncology Immuno Drug by Application
  1. 5.1 Oncology Immuno Drug Market by Application
  2. 5.1.1 Hospitals
  3. 5.1.2 Drugstores
  4. 5.1.3 Others
  5. 5.2 Global Oncology Immuno Drug Market Size by Application
  6. 5.2.1 Global Oncology Immuno Drug Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global Oncology Immuno Drug Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global Oncology Immuno Drug Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America Oncology Immuno Drug Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe Oncology Immuno Drug Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific Oncology Immuno Drug Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America Oncology Immuno Drug Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa Oncology Immuno Drug Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Bristol-Myers Squibb
  2. 6.1.1 Bristol-Myers Squibb Company Information
  3. 6.1.2 Bristol-Myers Squibb Business Overview
  4. 6.1.3 Bristol-Myers Squibb Oncology Immuno Drug Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Bristol-Myers Squibb Oncology Immuno Drug Product Portfolio
  6. 6.1.5 Bristol-Myers Squibb Recent Developments
  7. 6.2 Dendreon Pharmaceuticals
  8. 6.2.1 Dendreon Pharmaceuticals Company Information
  9. 6.2.2 Dendreon Pharmaceuticals Business Overview
  10. 6.2.3 Dendreon Pharmaceuticals Oncology Immuno Drug Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Dendreon Pharmaceuticals Oncology Immuno Drug Product Portfolio
  12. 6.2.5 Dendreon Pharmaceuticals Recent Developments
  13. 6.3 Gilead Sciences Inc.
  14. 6.3.1 Gilead Sciences Inc. Company Information
  15. 6.3.2 Gilead Sciences Inc. Business Overview
  16. 6.3.3 Gilead Sciences Inc. Oncology Immuno Drug Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Gilead Sciences Inc. Oncology Immuno Drug Product Portfolio
  18. 6.3.5 Gilead Sciences Inc. Recent Developments
  19. 6.4 Merck & Co
  20. 6.4.1 Merck & Co Company Information
  21. 6.4.2 Merck & Co Business Overview
  22. 6.4.3 Merck & Co Oncology Immuno Drug Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Merck & Co Oncology Immuno Drug Product Portfolio
  24. 6.4.5 Merck & Co Recent Developments
  25. 6.5 Sanofi S.A.
  26. 6.5.1 Sanofi S.A. Company Information
  27. 6.5.2 Sanofi S.A. Business Overview
  28. 6.5.3 Sanofi S.A. Oncology Immuno Drug Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Sanofi S.A. Oncology Immuno Drug Product Portfolio
  30. 6.5.5 Sanofi S.A. Recent Developments
  31. 6.6 AstraZeneca
  32. 6.6.1 AstraZeneca Company Information
  33. 6.6.2 AstraZeneca Business Overview
  34. 6.6.3 AstraZeneca Oncology Immuno Drug Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 AstraZeneca Oncology Immuno Drug Product Portfolio
  36. 6.6.5 AstraZeneca Recent Developments
  37. 6.7 Roche AG
  38. 6.7.1 Roche AG Company Information
  39. 6.7.2 Roche AG Business Overview
  40. 6.7.3 Roche AG Oncology Immuno Drug Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Roche AG Oncology Immuno Drug Product Portfolio
  42. 6.7.5 Roche AG Recent Developments
  43. 6.8 Merck KGaA
  44. 6.8.1 Merck KGaA Company Information
  45. 6.8.2 Merck KGaA Business Overview
  46. 6.8.3 Merck KGaA Oncology Immuno Drug Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Merck KGaA Oncology Immuno Drug Product Portfolio
  48. 6.8.5 Merck KGaA Recent Developments
  49. 6.9 Novartis
  50. 6.9.1 Novartis Company Information
  51. 6.9.2 Novartis Business Overview
  52. 6.9.3 Novartis Oncology Immuno Drug Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Novartis Oncology Immuno Drug Product Portfolio
  54. 6.9.5 Novartis Recent Developments
7 North America by Country
  1. 7.1 North America Oncology Immuno Drug Sales by Country
  2. 7.1.1 North America Oncology Immuno Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Oncology Immuno Drug Sales by Country (2021-2026)
  4. 7.1.3 North America Oncology Immuno Drug Sales Forecast by Country (2027-2032)
  5. 7.2 North America Oncology Immuno Drug Market Size by Country
  6. 7.2.1 North America Oncology Immuno Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Oncology Immuno Drug Market Size by Country (2021-2026)
  8. 7.2.3 North America Oncology Immuno Drug Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Oncology Immuno Drug Sales by Country
  2. 8.1.1 Europe Oncology Immuno Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Oncology Immuno Drug Sales by Country (2021-2026)
  4. 8.1.3 Europe Oncology Immuno Drug Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Oncology Immuno Drug Market Size by Country
  6. 8.2.1 Europe Oncology Immuno Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Oncology Immuno Drug Market Size by Country (2021-2026)
  8. 8.2.3 Europe Oncology Immuno Drug Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Oncology Immuno Drug Sales by Country
  2. 9.1.1 Asia-Pacific Oncology Immuno Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Oncology Immuno Drug Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Oncology Immuno Drug Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Oncology Immuno Drug Market Size by Country
  6. 9.2.1 Asia-Pacific Oncology Immuno Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Oncology Immuno Drug Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Oncology Immuno Drug Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Oncology Immuno Drug Sales by Country
  2. 10.1.1 South America Oncology Immuno Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Oncology Immuno Drug Sales by Country (2021-2026)
  4. 10.1.3 South America Oncology Immuno Drug Sales Forecast by Country (2027-2032)
  5. 10.2 South America Oncology Immuno Drug Market Size by Country
  6. 10.2.1 South America Oncology Immuno Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Oncology Immuno Drug Market Size by Country (2021-2026)
  8. 10.2.3 South America Oncology Immuno Drug Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Oncology Immuno Drug Sales by Country
  2. 11.1.1 Middle East and Africa Oncology Immuno Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Oncology Immuno Drug Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Oncology Immuno Drug Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Oncology Immuno Drug Market Size by Country
  6. 11.2.1 Middle East and Africa Oncology Immuno Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Oncology Immuno Drug Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Oncology Immuno Drug Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Oncology Immuno Drug Value Chain Analysis
  2. 12.1.1 Oncology Immuno Drug Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Oncology Immuno Drug Production Mode & Process
  7. 12.2 Oncology Immuno Drug Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Oncology Immuno Drug Distributors
  10. 12.2.3 Oncology Immuno Drug Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst